Desbois-Mouthon C - Search Results

1

Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.

Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O, Conti F, Praz F, Housset C, Rosmorduc O, Desbois-Mouthon C. Chettouh H, et al. Cancer Res. 2013 Jul 1;73(13):3974-86. doi: 10.1158/0008-5472.CAN-12-3824. Epub 2013 Apr 30. Cancer Res. 2013. PMID: 23633480

2

Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells.

Desbois-Mouthon C, Blivet-Van Eggelpoël MJ, Beurel E, Boissan M, Delélo R, Cadoret A, Capeau J. Desbois-Mouthon C, et al. Hepatology. 2002 Dec;36(6):1528-36. doi: 10.1053/jhep.2002.37192. Hepatology. 2002. PMID: 12447879

3

c-myc-induced hepatocarcinogenesis in the absence of IGF-I receptor.

Cadoret A, Desbois-Mouthon C, Wendum D, Leneuve P, Perret C, Tronche F, Housset C, Holzenberger M. Cadoret A, et al. Int J Cancer. 2005 Apr 20;114(4):668-72. doi: 10.1002/ijc.20805. Int J Cancer. 2005. PMID: 15609331

4

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.

Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O. Schiffer E, et al. Hepatology. 2005 Feb;41(2):307-14. doi: 10.1002/hep.20538. Hepatology. 2005. PMID: 15660382

5

Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma.

Boissan M, Beurel E, Wendum D, Rey C, Lécluse Y, Housset C, Lacombe ML, Desbois-Mouthon C. Boissan M, et al. Am J Pathol. 2005 Sep;167(3):869-77. doi: 10.1016/S0002-9440(10)62058-5. Am J Pathol. 2005. PMID: 16127164 Free PMC article.

6

Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout.

Desbois-Mouthon C, Wendum D, Cadoret A, Rey C, Leneuve P, Blaise A, Housset C, Tronche F, Le Bouc Y, Holzenberger M. Desbois-Mouthon C, et al. FASEB J. 2006 Apr;20(6):773-5. doi: 10.1096/fj.05-4704fje. Epub 2006 Feb 16. FASEB J. 2006. PMID: 16484330

7

Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.

Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O. Desbois-Mouthon C, et al. Int J Cancer. 2006 Dec 1;119(11):2557-66. doi: 10.1002/ijc.22221. Int J Cancer. 2006. PMID: 16988945

8

[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].

Fartoux L, Desbois-Mouthon C, Poupon R, Rosmorduc O. Fartoux L, et al. Gastroenterol Clin Biol. 2006 Oct;30(10):1133-5. doi: 10.1016/s0399-8320(06)73490-x. Gastroenterol Clin Biol. 2006. PMID: 17075466 Free article. Review. French. No abstract available.

9

Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.

Beurel E, Blivet-Van Eggelpoël MJ, Kornprobst M, Moritz S, Delelo R, Paye F, Housset C, Desbois-Mouthon C. Beurel E, et al. Biochem Pharmacol. 2009 Jan 1;77(1):54-65. doi: 10.1016/j.bcp.2008.09.026. Epub 2008 Oct 1. Biochem Pharmacol. 2009. PMID: 18938143

10

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.

Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O. Desbois-Mouthon C, et al. Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25. Clin Cancer Res. 2009. PMID: 19706799

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters